INHIBIKASE THERAPEUTICS INC (IKT)

Company Profile

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in developing protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. The company is headquartered in Atlanta, Georgia and currently employs 8 full-time employees. The company went IPO on 2020-12-23. The firm is focused on developing therapeutics for Parkinson’s disease and related disorders. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib (also known as IkT-148009), an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson’s-related disorders of the brain and GI tract, orphan indications related to Parkinson’s disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate. The Company’s RAMP medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain.

Company Info

INHIBIKASE THERAPEUTICS INC

3350 Riverwood Parkway Se, Suite 1900

Atlanta GEORGIA 30339

P: 16783923419

CEO: Milton H. Werner

Employees: 9

Website: https://www.inhibikase.com/